Abstract. microRNAs (miRNAs) are small non-coding RNA molecules of 21-24 nt that regulate the expression of other genes by transcriptional inhibition or translational repression. Multiple lines of evidence suggest that miRNAs play important roles in tumor development and progression.
Introduction microRNAs (miRNAs) are endogenous, small, single-stranded, non-coding RNAs that regulate the expression of a wide variety of genes by transcriptional inhibition or translational repression. Therefore, miRNAs function in diverse physiological and pathological processes. Since altered expression of miRNAs is reported in various types of cancers, it is reasonable to hypothesize that miRNAs play important roles in tumor development and progression. In fact, numerous studies have shown that miRNAs are involved in cell proliferation, apoptosis (1), differentiation (2) , reproduction (3) and cancer (4) . In addition, miRNAs also function as potential oncogenes or tumor-suppressor genes involved in tumor development and progression, and this has been well documented in many tumors, including pancreatic (5), colon (6) , gastric (7), breast (8) , liver (9) , lung (10) and nasopharyngeal cancer (11) .
Cervical cancer is the second most common malignancy in women worldwide, resulting in approximately 300,000 deaths each year. Yet, the underlying mechanisms of cervical cancer pathogenesis are still ill-defined. Emerging evidence indicates that miRNAs play a virtual role in the development of different types of cancers including cervical cancer. Wang et al (12) identified several aberrantly expressed miRNAs in cervical cancer. The expression of miR-143 was not only downregulated in cervical cancer tissue but also was lower in cervical cancer cell lines. Of particular interest, overexpression of miR-143 in HeLa cells successfully suppressed cell growth. Martinez et al (13) also suggested that the effect of miR-143 on cervical carcinogenesis is HPV-independent.
We are particularly interested in miR-143 and cervical cancer development. Using the programs RNA22, PICTAR4, PICTAR5, PITA, TargetScan, miR-143 was predicted to be able to interact with the 3'-UTR of Bcl-2 mRNA. It has been reported that Bcl-2 is sensitive to miR-143 in HCT116 human colorectal cancer cells (14) , and mechanistically miR-143 miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2 were cultured in RPMI-1640 medium (Invitrogen, USA) supplemented with 10% fetal bovine serum (FBS, Hyclone, USA), 2.05 mmol/l L-glutamine, 100 U/ml of penicillin and 100 µg/ml streptomycin at 37˚C, in 5% CO 2 . Total-RNA was extracted from the cancer tissues using TRIzol (Invitrogen) according to the manufacturer's instructions, and miRNAs were further purified using the MirVana miRNA Isolation kit (Ambion, Austin, TX, USA). The miRNA expression profiles were analyzed using MirVana miRNA Bioarray. Each array contains probes for all miRNAs in quadruplicate, and the signals obtained for each miRNA are represented as an average of four experiments. The small RNA fractions were fluorescently labeled and hybridized to the Bioarrays according to the manufacturer's instructions (Ambion). Each experiment was conducted twice. The Bioarrays were scanned using GenePix 4000B Scanner, and the median fluorescent intensity was obtained after subtracting the background using GenePix Pro 6.0 software.
Quantitative real-time PCR and RT-PCR.
The expression of the miRNAs was estimated using TaqMan MicroRNA assays (Applied Biosystems) with specific primers for miR-143 (P/N: 4373134, Applied Biosystems) in both the tissue samples and cultured cells. cDNA was reverse-transcribed from 10 ng of total RNA samples using the looped primers from the TaqMan MicroRNA assays and reagents from the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems). Real-time PCR was performed using the standard TaqMan miRNA assay protocol on an ABI7300 real-time PCR detection system. The snRNA U6 was used to normalize the expression levels of each miRNA. Bcl-2 mRNA was detected by RT-PCR. Total-RNA was isolated from cells using TRIzol (Invitrogen) and used for the firststrand cDNA synthesis with Superscript TM Reverse transcriptase and oligo(dt)18 primer according to the manufacturer's protocol (Life Technologies, Gaithersburg, MD, USA). Bcl-2 sense primer was 5'-CGACGACTTCTCCCGCCGCTACCGC-3' and antisense primer, 5'-CCGCTAGCTGGGGCCGTACA GTTCC-3' . The expected size of the product is 318 bp. β-actin was used as the internal control. β-actin sense primer was 5'-CATCCTGCGTCTGGACCT-3' and antisense primer, 5'-CAGGAGGAGCAATGATCTTG-3' with a predicted product of 480 bp. The PCR products were separated on 1.5% agarose gel.
Construction of the plasmids and transfection. To construct the plasmid expressing miR-143, synthesized precursor miR-143 (pre-miR-143) and antisense-miR-143 (pre-antimiR-143) (Cell Biolabs, USA) were inserted into the miRNASelect™ pEGP-miR vector (Cell Biolabs). The control miRNA was inserted similarly into the miRNASelect TM pEP-miR vector (Cell Biolabs). All the vectors were capable of expressing the GFP biomarker. Positive clones were selected using puromycin, and finally, qRT-PCR was performed to verify indirectly the sequence of miR-143. For overexpression of Bcl-2, the open reading frame of the Bcl-2 was inserted into the pCMV6-AC-RFP vector (OriGene, USA). To construct the luciferase reporter, the 3'-UTR of the Bcl-2, containing the miR-143-binding sequence (CAUCUCA, 1811-1817 bp) was amplified by RT-PCR; sense primer, 5'-CCGTGTTTAATGCTGTGGTTGA-3' and antisense primer, 5'-GCCAGTGACATCCAGGTTTTTCTTA-3' with a predicted product of 229 bp, was inserted into the pMIR-REPORT TM miRNA Expression Reporter Vector from Ambion (pMIR-Bcl-2). The pMIR-Bcl-2-mut was constructed in a similar way except the A's in the CAUCUCA were mutated into G's using a Site-Directed Mutagenesis kit (Stratagene, USA) according to the manufacturer's instructions. The HeLa cells were seeded in 6-well plates at 20x10 4 cells/well and after growing overnight to 70-80% confluence, the cells were transfected with the different plasmids.
MTT assay. The cells were suspended in 200 µl medium and seeded in 96-well plates (1x10 4 /ml) and grown to 50% confluence and synchronized with serum-free medium for 24 h before the serum concentration was brought to 10%. Then 20 µl MTT reagent (5 mg/ml; Amresco, USA) was added at different time points (24, 48 and 72 h). After incubation at 37˚C for 4 h and a brief centrifugation, 150 µl of DMSO was added to halt the reaction. The cell confluence was determined by the absorbance at 570 nm.
Apoptosis assay. Cell death as a result of apoptosis was evaluated using a cell death detection ELISA-Plus kit (Roche Molecular Biochemicals, USA). HeLa cells infected with pre-miR-143, pre-anti-miR-143 or control miRNA precursor were plated in triplicate in 6-well plates. Cells were serum-deprived for 24 h and then lysed, and the cytoplasmic histone-associated DNA fragmentation (mono-and oligonucleosomes) was detected by spectrophotometry according to the manufacturer's instructions.
Xenograft tumor model. To evaluate in vivo tumorigenesis, a cervical cancer xenografting mouse model was used.
Female athymic nude mice (nu/nu, 3 to 4-weeks old) were purchased from Shanghai Laboratory Animal Co., Ltd. (SLAC, Shanghai, China) and maintained in the Laboratory for Experiments, Central South University under laminar airflow conditions. The studies were conducted in accordance with the standards established by the Guidelines for the Care and Use of Laboratory Animals by Central South University. All procedures involving mice were approved by the Central South University Animal Management Committee. HeLa cells (5x10 6 ) transfected with pre-miR-143, pre-anti-miR-143 or control miRNA precursor were injected subcutaneously into the flanks of nude mice (6 mice/group). The volume (V) of the implanted tumor was measured every 3rd day with a vernier caliper, and the tumor sizes were estimated using the formula: V (mm 3 ) = length x width 2 x 0.5. Tumor xenografts were harvested, weighed and snap-frozen 4 weeks after inoculation.
Western blot analysis. The protein lysate was separated by 8% SDS-PAGE and transferred onto a PVDF transfer membrane (Bio-Rad, USA). After blocking in a 10% skim milk solution, membranes were incubated overnight at 4˚C with anti-Bcl-2 (Santa Cruz Biotechnology, USA). Then they were further incubated for 45 min with goat anti-rabbit horseradish peroxidase (HRP)-coupled secondary antibodies (Boster, China) at room temperature. Immunoreactive proteins were detected by the enhanced chemiluminescence reagent (Amersham, USA), and the chemilluminescent signal on the blot was exposed to X-Omat BTFilm (Kodak, China). The density of the band was quantified and β-actin was used as the internal standard for all membranes.
Luciferase activity assay. HeLa cells were seeded in 24-well plates 24 h prior to transfection. pMIR-Bcl-2 or pMIR-Bcl-2-mut luciferase vectors were co-transfected with a control pRL-TK vector (Promega, Madison, WI, USA) into HeLa cells together with pre-miR-143 or control miRNA. The pRL-TK vector (Promega) containing Renilla luciferase was an internal reference. Firefly and Renilla luciferase activities were measured using the dual-luciferase reporter assay (Promega) 24 h after transfection. Firefly luciferase activity was normalized to Renilla luciferase activity. The experiments were performed in triplicate.
Statistical analyses. Differential expression of miRNA in the surgical samples was determined by testing the null hypothesis that the mean of the log 2 -transformed values of the fold change was equal to 0 by one-sample t-test. The data were analyzed by one-way analysis of variance and the Student's t-test to determine statistical significance using SPSS 16.0 statistic software. Each experiment was repeated at least three times. The results were expressed as mean ± SD. Outcomes were considered statistically significant with two-tailed P<0.05.
Results

miR-143 is downregulated in cancerous cervical tissues.
To investigate the miRNA expression profile of cervical cancer, we initially collected 15 pairs of primary cancerous cervical tissues and their pair-matched non-tumor tissues, and compared their miRNA expression by miRNA microarray analysis. A total of 24 miRNAs showed significantly differential expression in cancerous cervical tissues when compared to the matched non-tumor tissues. miR-16, miR-21, miR-205 and miR-199a were overexpressed and miR-143, let-7c, miR-203, miR-196b, miR-149 and miR-145 were downregulated (Table I) . miR-143 was also found to be the most downregulated in the cancerous cervical tissues. To further confirm our findings, the levels of miR-143 in the cancer tissues of 15 patients were validated by qRT-PCR. We found that miR-143 was downregulated in 86.7% of these cases (13 of 15 patients, P<0.01) (Fig. 1) . These data suggest that miR-143 is frequently downregulated in cancerous cervical tissues.
miR-143 inhibits HeLa cell proliferation and promotes apoptosis in vitro.
HeLa cells were transfected with plasmids expressing pre-miR-143, pre-anti-miR-143 or control miRNA precursor, respectively. qRT-PCR analysis validated that the plasmids had been integrated into the genome of the HeLa cells.
More importantly, expression of miR-143 was significantly increased in the HeLa cells transfected with pre-miR-143 and was decreased in cells transfected with pre-anti-miR-143 compared to the control miRNA precursor ( Fig. 2A) .
To evaluate the effects of miR-143 on HeLa cells, we explored the changes in cell proliferation and apoptosis ( Fig. 2B and C) . Cell proliferation of the miR-143-transfected HeLa cells was decreased by 13.54% at 24 h, 18.63% at 48 h, and the relative apoptosis was increased by 75.34% and 80.81%, respectively; while cell proliferation of the anti-miR-143-transfected group was increased by 9.38% at 24 h and 13.66% at 48 h, and the relative apoptosis was decreased by 23.97% and 27.90%, respectively. The results revealed that miR-143 significantly inhibited the proliferation of HeLa cells and promoted apoptosis, whereas anti-miR-143 had opposite effects. Compared to the control, miR-143 modestly affected the proliferation and apoptosis at 12 h, but had a strong affect at 48 h. This suppressive or enhancing effect was not an immediate cell response. These results indicate that miR-143 may play a role in the proliferation and apoptosis of HeLa cells in vitro; anti-miR-143 partially reverse the role, and this effect required an interval of time.
miR-143 suppresses xenograft tumor formation. Since miR-143 inhibited HeLa cell proliferation in vitro, we further assessed its effect on tumor formation in vivo. HeLa cells (5x10 6 ) were first transfected with pre-miR-143, pre-anti-miR-143 or control miRNA precursor, respectively, and the stable cell lines were selected by puromycin. The three cell lines were injected subcutaneously into the flanks of nude mice. The volume of the implanted tumor was measured every 3 days. Tumor xenografts were collected and weighed 4 weeks after inoculation. miR-143 markedly reduced tumor size (Fig. 3A and B ) and tumor weight (Fig. 3C) . However, anti-miR-143 partially reversed the effect. Our data suggest that miR-143 suppresses xenograft tumor formation in HeLa cells in vivo.
miR-143 inhibits Bcl-2 expression. In order to investigate the molecular mechanism of miR-143 action in cervical cancer, the prediction programs RNA22, PICTAR4, PICTAR5, PITA and TargetScan were used, and miR-143 was predicted to be associated with Bcl-2 mRNA at its 3'-UTR. Bcl-2 was further studied as a potential target. We examined the expression levels of Bcl-2 protein and mRNA in miR-143 downregulated tissues, compared to the normal cervical tissues. The expression levels of Bcl-2 protein and mRNA were increased in all tissues with miR-143 downregulation (Fig. 4A and B) . In order to further confirm the effect of miR-143 on Bcl-2, we detected the expression of Bcl-2 in HeLa cells transfected with pre-miR-143, pre-anti-miR-143 or control miRNA precursor, respectively. As shown in Fig. 4C and D, compared with the control, the Bcl-2 protein and mRNA levels were significantly reduced in the miR-143-transfected HeLa cells. On the other hand, the levels of Bcl-2 were clearly increased in the HeLa cells transfected with anti-miR-143. Our results suggest that the expression of miR-143 and Bcl-2 have an opposite relation, and miR-143 may inhibit the expression of Bcl-2. 
A B C D
Bcl-2 is a target of miR-143.
To test whether miR-143 regulates Bcl-2 directly, we expressed Bcl-2 alone or together with miR-143 in HeLa cells. Western blotting further verified that the Bcl-2 protein was highly expressed in the Bcl-2-transfected HeLa cells (Fig. 5A ). More importantly, miR-143 attenuated the Bcl-2 levels. Furthermore, results from the MTT assay showed the effect, of Bcl-2 on cell proliferation (Fig. 5B) .
The proliferation of the miR-143-transfected HeLa cells was reduced, while the proliferation of the Bcl-2-transfected HeLa cells was significantly increased by 11.40% at 24 h and 20.43% at 48 h, and the effect mediated by Bcl-2 was weakened when the HeLa cells were co-transfected with pre-miR-143. There were no obvious differences between the control miRNA and pCMV6-AC-RFP controls. The apoptotic results had an opposite trend to the Bcl-2 levels (Fig. 5C) ; apoptosis was inhibited by 13.89% at 24 h and 21.21% at 48 h when Bcl-2 was overexpressed. However, when the HeLa cells were co-transfected with pre-miR-143, the Bcl-2-mediated effects were clearly weakened. Together with the results from Fig. 4 , these data suggest that Bcl-2 may be a target of miR-143. In order to validate the predicted miR-143-binding sites in the 3'-UTR of the Bcl-2 mRNA, the Bcl-2 luciferase reporter assays were employed. The pMIR-Bcl-2 luciferase vector was transfected into the HeLa cells together with either the control miRNA or the pre-miR-143. Compared with the control miRNA, transfection of the pre-miR-143 significantly decreased the reporter luciferase activity (Fig. 5D) . In addition, mutation of the seed region abrogated the suppression of A B C D luciferase activity caused by miR-143 (Fig. 5D) . In contrast, the luciferase activity in cells transfected with pMIR-REPORT firefly luciferase reporter control vector without the 3'-UTR of the Bcl-2 mRNA was not affected. These data strongly suggest that Bcl-2 is a target of miR-143.
Discussion
It has been reported that miR-143 is downexpressed in colon (15) , lung (16) and prostate cancer (17) and is overexpressed in hepatocarcinoma (18) . Furthermore, miR-143 is involved in the regulation of MYO6 expression in prostate cancer (17); extracellular signal-regulated kinase-5 (ERK-5) is a miR-143 target in prostate cancer and miR-143 inhibits the proliferation at least in part by the inhibition of ERK-5 activity (19) . Restoration of miR-143 expression in colon cancer cell lines was forced to not only decreased tumor cell growth and soft-agar colony formation, but also downregulated the DNMT3A at both the mRNA and protein levels (20 (21) found that miR-218 inhibited the proliferation of HeLa cells and induced apoptosis. In their study, miR-214 was downregulated in cervical cancer compared with normal tissue. Overexpression of miR-214 in HeLa cells also significantly inhibited cell proliferation. In addition, HeLa cells that stably overexpressed miR-214 downregulated the expression of MEK3 and JNK1 at both the mRNA and protein levels by targeting the 3'UTRs of these genes (22) . Finally, it has been reported that miR-34a inhibits invasiveness through regulation of the Notch pathway and its downstream matrix degrading enzyme in cervical cancer (23) . In our study, we found that miR-143 was underexpressed in 86.7% of the cancerous cervical tissues compared with their non-tumor counterparts. This is consistent with other reports (12, 13) . Furthermore, miR-143 not only suppressed HeLa cell proliferation and promoted apoptosis, but also inhibited the tumor formation in nude mice. Our data clearly showed that overexpression of miR-143 significantly decreased Bcl-2 expression, and anti-miR-143 elevated it, which indicate that miR-143 regulates expression of Bcl-2. Given the widely reported effects of miR-143 in different tumors, it may be developed as a novel tumor biomarker for diagnosis. Zhang et al (24) found that miR-143 was downregulated in osteosarcoma cell lines and primary tumor samples, and the restoration of miR-143 reduced cell viability, promoted cell apoptosis and suppressed tumorigenicity. Additionally, Bcl-2 was identified to be a direct target of miR-143. Taken together, since the expression of miR-143 and Bcl-2 is inversely related in different types of cancers, these two biomarkers could be used simultaneously to increase diagnostic accuracy.
It is well established that Bcl-2 is an apoptosis-related protein. Overexpression of Bcl-2 is closely related to multiple epithelial tumors resulting from DNA damage and continued survival and subsequently aggregated mutations. Furthermore, the presence of the Bcl-2 protein is strongly associated with the development of invasive cervical disease (25) and Bcl-2 was significantly correlated to the grades of cervical intraepithelial neoplasia (26) . The apoptotic effect of miR-29 is Mcl-1-and Bcl-2-dependent (27) . It has been suggested that miR-181a, a regulator of Bcl-2, may be targeted to enhance the effect of radiation treatment for malignant glioma cells (28) . Both miR-15b and miR-16 could play an important role in the development of MDR in gastric cancer cell apoptosis via Bcl-2 (29) . Here, we confirmed that the overexpression of Bcl-2 is associated with cervical cancer. Furthermore, overexpression of Bcl-2 showed similar effects as anti-miR-143 expression, which was attenuated by the overexpression of miR-143. Bcl-2 was confirmed to be a target of miR-143 in this study. This indicates that the suppressive effects of miR-143 in HeLa cell proliferation and promotion of apoptosis is, at least in part, through suppression of the expression of Bcl-2. Thus, manipulation of Bcl-2 expression by targeting miR-143 could be used as a therapeutic strategy in cervical cancer treatment.
In conclusion, we demonstrated that miR-143 is downregulated in cervical cancer. Transfection experiments demonstrated that miR-143 serves as a tumor suppressor inhibiting HeLa cell proliferation and promoting apoptosis. miR-143 has the capacity to suppress the formation of tumor in nude mice. Mechanistically, these effects are Bcl-2-dependent. Therefore, miR-143 levels could be used as a biomarker in facilitating cervical tumor diagnosis. Finally, targeting miR-143 could be developed into a powerful therapeutic treatment for cervical cancer.
